Cargando…

Expression analysis of cytokines IL-5, IL-6, IL-8, IL-17 and VEGF in breast cancer patients

OBJECTIVE: To investigate the relationship between changes in peripheral blood vascular endothelial growth factor (VEGF), interleukin-5 (IL-5), interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-17 (IL-17) concentrations in breast cancer patients and their significance and clinical value in...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Gang, Chen, Xiang-Ting, Zhang, Hao, Chen, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753904/
https://www.ncbi.nlm.nih.gov/pubmed/36531035
http://dx.doi.org/10.3389/fonc.2022.1019247
_version_ 1784851070250385408
author Liu, Gang
Chen, Xiang-Ting
Zhang, Hao
Chen, Xin
author_facet Liu, Gang
Chen, Xiang-Ting
Zhang, Hao
Chen, Xin
author_sort Liu, Gang
collection PubMed
description OBJECTIVE: To investigate the relationship between changes in peripheral blood vascular endothelial growth factor (VEGF), interleukin-5 (IL-5), interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-17 (IL-17) concentrations in breast cancer patients and their significance and clinical value in breast cancer staging and invasive metastasis. METHODS: From September 2021 to April 2022, 60 breast cancer patients from Chongqing Medical University Hospital No. 2022 were enrolled in the breast breast cancer surgery group, while 30 patients with benign breast disease were enrolled in the control group during the same period. Venous blood samples were collected at admission and 1 week after surgery to determine the expression of these factors in serum. Statistical methods such as Wilcoxon test and Spearman correlation analysis were used to analyze the relationship between the above factors and the clinicopathological characteristics of the patients. RESULTS: By analyzing data from patients with benign and malignant breast tumors, an association was found with serum levels of IL-6, IL-17 and VEGF. Their respective areas under the operating characteristic curve were 0.649, 0.734 and 0.656 (P < 0.05). There were significant differences in the cytokine expression levels of IL-17 and VEGF in different molecular typing (P values were 0.008 and 0.040, respectively). The expression levels of IL-17 and VEGF were higher in HER-2 receptor-positive and triple-negative patients than in hormone receptor-positive patients (P < 0.05). Also, no significant correlation was found between the various cytokines mentioned in the article and breast cancer lymph node metastasis and Tumor Node Metastasis stage (TNM stage). In addition, in the breast cancer surgery group, postoperative VEGF levels were lower (P < 0.05) and IL-6 levels were higher (P < 0.05) compared to preoperative levels. CONCLUSIONS: Serum IL-6, IL-17, and VEGF are strongly associated with breast cancer development and can be used as a reference indicators for breast cancer diagnosis. In addition, post-operative VEGF levels decreases and IL-6 levels increases compared to pre-operative levels, which can also be used as an a postoperative follow-up indicator. In contrast, IL-5 and IL-8 have not found to be significantly associated with breast cancer patients in this study, which requires further study.
format Online
Article
Text
id pubmed-9753904
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97539042022-12-16 Expression analysis of cytokines IL-5, IL-6, IL-8, IL-17 and VEGF in breast cancer patients Liu, Gang Chen, Xiang-Ting Zhang, Hao Chen, Xin Front Oncol Oncology OBJECTIVE: To investigate the relationship between changes in peripheral blood vascular endothelial growth factor (VEGF), interleukin-5 (IL-5), interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-17 (IL-17) concentrations in breast cancer patients and their significance and clinical value in breast cancer staging and invasive metastasis. METHODS: From September 2021 to April 2022, 60 breast cancer patients from Chongqing Medical University Hospital No. 2022 were enrolled in the breast breast cancer surgery group, while 30 patients with benign breast disease were enrolled in the control group during the same period. Venous blood samples were collected at admission and 1 week after surgery to determine the expression of these factors in serum. Statistical methods such as Wilcoxon test and Spearman correlation analysis were used to analyze the relationship between the above factors and the clinicopathological characteristics of the patients. RESULTS: By analyzing data from patients with benign and malignant breast tumors, an association was found with serum levels of IL-6, IL-17 and VEGF. Their respective areas under the operating characteristic curve were 0.649, 0.734 and 0.656 (P < 0.05). There were significant differences in the cytokine expression levels of IL-17 and VEGF in different molecular typing (P values were 0.008 and 0.040, respectively). The expression levels of IL-17 and VEGF were higher in HER-2 receptor-positive and triple-negative patients than in hormone receptor-positive patients (P < 0.05). Also, no significant correlation was found between the various cytokines mentioned in the article and breast cancer lymph node metastasis and Tumor Node Metastasis stage (TNM stage). In addition, in the breast cancer surgery group, postoperative VEGF levels were lower (P < 0.05) and IL-6 levels were higher (P < 0.05) compared to preoperative levels. CONCLUSIONS: Serum IL-6, IL-17, and VEGF are strongly associated with breast cancer development and can be used as a reference indicators for breast cancer diagnosis. In addition, post-operative VEGF levels decreases and IL-6 levels increases compared to pre-operative levels, which can also be used as an a postoperative follow-up indicator. In contrast, IL-5 and IL-8 have not found to be significantly associated with breast cancer patients in this study, which requires further study. Frontiers Media S.A. 2022-12-01 /pmc/articles/PMC9753904/ /pubmed/36531035 http://dx.doi.org/10.3389/fonc.2022.1019247 Text en Copyright © 2022 Liu, Chen, Zhang and Chen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Liu, Gang
Chen, Xiang-Ting
Zhang, Hao
Chen, Xin
Expression analysis of cytokines IL-5, IL-6, IL-8, IL-17 and VEGF in breast cancer patients
title Expression analysis of cytokines IL-5, IL-6, IL-8, IL-17 and VEGF in breast cancer patients
title_full Expression analysis of cytokines IL-5, IL-6, IL-8, IL-17 and VEGF in breast cancer patients
title_fullStr Expression analysis of cytokines IL-5, IL-6, IL-8, IL-17 and VEGF in breast cancer patients
title_full_unstemmed Expression analysis of cytokines IL-5, IL-6, IL-8, IL-17 and VEGF in breast cancer patients
title_short Expression analysis of cytokines IL-5, IL-6, IL-8, IL-17 and VEGF in breast cancer patients
title_sort expression analysis of cytokines il-5, il-6, il-8, il-17 and vegf in breast cancer patients
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753904/
https://www.ncbi.nlm.nih.gov/pubmed/36531035
http://dx.doi.org/10.3389/fonc.2022.1019247
work_keys_str_mv AT liugang expressionanalysisofcytokinesil5il6il8il17andvegfinbreastcancerpatients
AT chenxiangting expressionanalysisofcytokinesil5il6il8il17andvegfinbreastcancerpatients
AT zhanghao expressionanalysisofcytokinesil5il6il8il17andvegfinbreastcancerpatients
AT chenxin expressionanalysisofcytokinesil5il6il8il17andvegfinbreastcancerpatients